BiotechTube

everolimus + low-dose tacrolimus

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Highly-sensitized Kidney Transplant Recipients

Conditions

Highly-sensitized Kidney Transplant Recipients

Trial Timeline

Jun 1, 2013 → Jan 19, 2016

NCT ID
NCT01911546

About everolimus + low-dose tacrolimus

everolimus + low-dose tacrolimus is a phase 2 stage product being developed by Novartis for Highly-sensitized Kidney Transplant Recipients. The current trial status is completed. This product is registered under clinical trial identifier NCT01911546. Target conditions include Highly-sensitized Kidney Transplant Recipients.

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01911546Phase 2Completed